Abstract

The goal of the Biospecimen Processing Core (BPC, Core A) is to provide high-quality, clinically annotated biospecimens to all five research projects in this SPORE application as well as ongoing and future SPORE- sponsored DRP and CEP projects, and to serve as an unparalleled biospecimen resource to the broader cancer research community. The BPC will be responsible for the identification and enrollment of every patient referred to the Siteman Cancer Center with newly diagnosed and relapsed hematologic malignancy (excluding multiple myeloma). Biospecimens from these patients will be collected, processed, and stored by leveraging the extensive infrastructure of the Siteman Cancer Center Tissue Procurement Core (TPC), a CAP-accredited biorepository with over 15 years of experience in biospecimen banking. Clinical data will be collected prospectively by integrating with and extending the mission of an existing Clinical Database Core (CDC), previously established as part of the Genomics of AML (GAML) Program Project to serve as a platform for the investigation of genetic mutations associated with the pathogenesis of MDS and AML. As such, Core A will continue to supplement Cancer Center resources with focused expertise and effort to comprehensively collect, annotate, quality review, and distribute biospecimens specifically for translational leukemia and leukemia- related cancer research.
Specific Aims i nclude:
Specific Aim 1. To provide expertise in biobanking and clinical annotation to specifically support projects 1- 5 in this SPORE application.
Specific Aim 2. To provide an on-going, high quality, clinically annotated biospecimen resource of hematological malignancy patient biospecimens for other translational research projects both within and external to this SPORE program.
Specific Aim 3 : To create a comprehensive and transparent plan to catalog collected biospecimens and facilitate their distribution to the broader scientific community of hematologic malignancy investigators.

Public Health Relevance

This core will provide high-quality, clinically annotated biospecimens to all five research projects in this SPORE as well as ongoing and future SPORE-sponsored projects, and it will serve as an unparalleled biospecimen resource to the broader cancer research community.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA171963-08
Application #
9961533
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
8
Fiscal Year
2020
Total Cost
Indirect Cost

  Institution

Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130

  Publications

Duncavage, Eric J; Jacoby, Meagan A; Chang, Gue Su et al. (2018) Mutation Clearance after Transplantation for Myelodysplastic Syndrome. N Engl J Med 379:1028-1041
Khoury, Hanna Jean; Langston, Amelia A; Kota, Vamsi K et al. (2018) Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease. Bone Marrow Transplant 53:826-831
Schroeder, Mark A; Choi, Jaebok; Staser, Karl et al. (2018) The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia. Biol Blood Marrow Transplant 24:1125-1134
Perry, Justin S A; Russler-Germain, Emilie V; Zhou, You W et al. (2018) CD36 Mediates Cell-Surface Antigens to Promote Thymic Development of the Regulatory T Cell Receptor Repertoire and Allo-tolerance. Immunity 48:923-936.e4
Wong, Terrence N; Miller, Christopher A; Jotte, Matthew R M et al. (2018) Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential. Nat Commun 9:455
Christopher, Matthew J; Petti, Allegra A; Rettig, Michael P et al. (2018) Immune Escape of Relapsed AML Cells after Allogeneic Transplantation. N Engl J Med 379:2330-2341
Trissal, Maria C; Wong, Terrence N; Yao, Juo-Chin et al. (2018) MIR142 Loss-of-Function Mutations Derepress ASH1L to Increase HOXA Gene Expression and Promote Leukemogenesis. Cancer Res 78:3510-3521
Jacoby, Meagan A; Duncavage, Eric J; Chang, Gue Su et al. (2018) Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant. JCI Insight 3:
Monlish, Darlene A; Bhatt, Sima T; Duncavage, Eric J et al. (2018) Loss of Toll-like receptor 2 results in accelerated leukemogenesis in the NUP98-HOXD13 mouse model of MDS. Blood 131:1032-1035
Choi, Jaebok; Cooper, Matthew L; Staser, Karl et al. (2018) Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease. Leukemia 32:2483-2494

Showing the most recent 10 out of 64 publications